Skip to content
lifestyle.menstyle1.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Moderna, Inc.
Moderna and Merck Present 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA (pembrolizumab) in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection at the 2026 ASCO Annual Meeting
June 1, 2026
Moderna and Merck Present 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA (pembrolizumab) in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection at the 2026 ASCO Annual Meeting
June 1, 2026
Moderna and CEPI Expand Strategic Collaboration to Advance Potential Vaccine Against Bundibugyo Ebolavirus
June 1, 2026
Moderna Recognized by TIME as One of the World’s Most Impactful Companies
May 21, 2026
Moderna Announces New England Journal of Medicine Publication of Pivotal Phase 3 Clinical Safety and Efficacy Data for Its Investigational Seasonal Influenza Vaccine, mRNA-1010
May 6, 2026
Moderna Reports First Quarter 2026 Financial Results and Provides Business Updates
May 1, 2026
Moderna Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Updates
February 14, 2026
Moderna Receives Refusal-to-File Letter from the U.S. Food and Drug Administration for Its Investigational Seasonal Influenza Vaccine, mRNA-1010
February 13, 2026
Moderna to Enter into Long-Term Strategic Agreement with the Government of Mexico
February 12, 2026
←
Previous Page
1
2
3